Wall Street analysts forecast that Antares Pharma, Inc. (NASDAQ:ATRS) will report $14.44 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Antares Pharma’s earnings. The highest sales estimate is $17.00 million and the lowest is $12.38 million. Antares Pharma reported sales of $13.42 million during the same quarter last year, which indicates a positive year-over-year growth rate of 7.6%. The firm is scheduled to report its next earnings results on Tuesday, August 14th.
According to Zacks, analysts expect that Antares Pharma will report full year sales of $62.57 million for the current year, with estimates ranging from $58.20 million to $67.20 million. For the next fiscal year, analysts anticipate that the business will report sales of $103.65 million per share, with estimates ranging from $80.60 million to $126.72 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Antares Pharma.
Get Antares Pharma alerts:Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). The company had revenue of $12.70 million for the quarter, compared to analyst estimates of $12.85 million. Antares Pharma had a negative return on equity of 52.74% and a negative net margin of 32.96%.
Several analysts have recently commented on the stock. HC Wainwright set a $4.00 price objective on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Tuesday, May 8th. ValuEngine raised shares of Antares Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, BidaskClub raised shares of Antares Pharma from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 1st. One analyst has rated the stock with a hold rating, three have given a buy rating and two have given a strong buy rating to the stock. Antares Pharma presently has an average rating of “Buy” and an average target price of $3.86.
In related news, Director Jacques Gonella sold 200,000 shares of Antares Pharma stock in a transaction on Friday, May 11th. The shares were sold at an average price of $2.42, for a total value of $484,000.00. Following the completion of the sale, the director now owns 11,686,413 shares of the company’s stock, valued at approximately $28,281,119.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last three months, insiders sold 900,000 shares of company stock valued at $2,233,000. 11.60% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. grew its position in Antares Pharma by 5.1% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 560,936 shares of the specialty pharmaceutical company’s stock valued at $1,818,000 after purchasing an additional 27,360 shares during the period. Raymond James Financial Services Advisors Inc. grew its position in Antares Pharma by 34.9% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 180,666 shares of the specialty pharmaceutical company’s stock valued at $360,000 after purchasing an additional 46,766 shares during the period. MetLife Investment Advisors LLC grew its position in Antares Pharma by 281.1% in the 1st quarter. MetLife Investment Advisors LLC now owns 71,731 shares of the specialty pharmaceutical company’s stock valued at $158,000 after purchasing an additional 52,911 shares during the period. Virtu Financial LLC acquired a new stake in Antares Pharma in the 4th quarter valued at $117,000. Finally, BlackRock Inc. grew its position in Antares Pharma by 0.9% in the 4th quarter. BlackRock Inc. now owns 9,340,209 shares of the specialty pharmaceutical company’s stock valued at $18,587,000 after purchasing an additional 83,916 shares during the period. 35.74% of the stock is owned by institutional investors and hedge funds.
Shares of ATRS stock opened at $2.52 on Friday. The company has a market cap of $403.04 million, a PE ratio of -22.91 and a beta of 0.19. Antares Pharma has a 52 week low of $1.58 and a 52 week high of $4.09. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.94 and a quick ratio of 2.39.
About Antares Pharma
Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Get a free copy of the Zacks research report on Antares Pharma (ATRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment